title: Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.
authors.affiliation: Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy, 9713 AV Groningen, The Netherlands. m.postma@farm.rug.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: Postma
authors.forename: J M
authors.initials: JM
authors.lastname: Bos
authors.forename: R
authors.initials: R
authors.lastname: Welte
authors.forename: R
authors.initials: R
authors.lastname: de Groot
authors.forename: W
authors.initials: W
authors.lastname: Luytjes
authors.forename: H C
authors.initials: HC
authors.lastname: Rümke
authors.forename: P
authors.initials: P
authors.lastname: Beutels
mesh_terms: D002644:Chickenpox / Q000191:economics* / Q000517:prevention & control; D019433:Chickenpox Vaccine / Q000191:economics*; D002648:Child; D005858:Germany; D017048:Health Care Costs; D006562:Herpes Zoster / Q000191:economics / Q000517:prevention & control; D006801:Humans; D007223:Infant; D032541:Mass Vaccination / Q000191:economics*
chemical_list: D019433:Chickenpox Vaccine